120 related articles for article (PubMed ID: 38777864)
21. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
22. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
24. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
25. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
26. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
29. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.
Chao C; Page JH; Yang SJ; Rodriguez R; Huynh J; Chia VM
Ann Oncol; 2014 Sep; 25(9):1821-1829. PubMed ID: 24915871
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
32. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
[TBL] [Abstract][Full Text] [Related]
33. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Wang XJ; Lopez SE; Chan A
Crit Rev Oncol Hematol; 2015 May; 94(2):201-12. PubMed ID: 25600838
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
35. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
37. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia.
Chindaprasirt J; Wanitpongpun C; Limpawattana P; Thepsuthammarat K; Sripakdee W; Sookprasert A; Wirasorn K
Asian Pac J Cancer Prev; 2013; 14(2):1115-9. PubMed ID: 23621197
[TBL] [Abstract][Full Text] [Related]
38. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore.
Zhou YP; Jin J; Ding Y; Chee YL; Koh LP; Chng WJ; Chan DS; Hsu LY
Support Care Cancer; 2014 Jun; 22(6):1447-51. PubMed ID: 24287505
[TBL] [Abstract][Full Text] [Related]
39. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.
Sato R; Gomez Rey G; Nelson S; Pinsky B
Appl Health Econ Health Policy; 2013 Jun; 11(3):251-8. PubMed ID: 23605251
[TBL] [Abstract][Full Text] [Related]
40. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
